Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Amicus drug fails to heal wounds in patients with rare, skin-blistering disease

  • Adam Feuerstein

By Adam Feuerstein Sept. 13, 2017

Reprints

Amicus Therapeutics (FOLD) announced negative results Wednesday from a late-stage clinical trial of an experimental topical medicine for patients suffering from a rare, inherited skin-blistering disease.

In the phase 3 clinical trial, the Amicus drug SD-101 did no better than placebo in healing wounds in patients with epidermolysis bullosa.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

FDA offers radio silence on question of spring Covid…
FDA offers radio silence on question of spring Covid boosters, as other countries push ahead
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Why you get paid to donate plasma but not…
Why you get paid to donate plasma but not blood
Patient groups balk at former AstraZeneca official negotiating U.K.-India…
Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
Altimmune’s obesity drug fails to stand out from blockbuster…
Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data
Pharmalittle: FDA official wants to use accelerated approval for…
Pharmalittle: FDA official wants to use accelerated approval for gene therapies; pharma asks Biden for tax…

Recommended Stories